Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 37Cytarabine 27Methotrexate 22Dexamethasone 20Vincristine 19fludarabine 15Mercaptopurine 14Etoposide 14Radiotherapy 12Daunorubicin 12Asparaginase 12Doxorubicin 11Prednisolone 9Idarubicin 9Busulfan 8pegaspargase 7blinatumomab 7Peripheral Blood Stem Cell Transplantation 6Melphalan 6Immunotherapy, Adoptive 6Imatinib Mesylate 6Dasatinib 6fludarabine phosphate 5Prednisone 5Methylprednisolone 5Filgrastim 5Whole-Body Irradiation 4Thioguanine 4Rituximab 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precursor Cell Lymphoblastic Leukemia-Lymphoma × flumatinib × Clear all
NCT04375683 2022-03-24

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Zhongda Hospital

Phase 3 Unknown
28 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡